Repligen vs Personalis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Repligen Corporation (RGEN)

Q3 202630 Jun – 28 Jul 2026

▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.
This is the biggest new event driving RGEN's price, showing a major growth move.
Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.
This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.
Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.
It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.
Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.
This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

July 202630 Jun – 28 Jul 2026

▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.
This is the biggest new event driving RGEN's price, showing a major growth move.
Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.
This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.
Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.
It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.
Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.
This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Latest30 Jun – 28 Jul 2026

▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.
This is the biggest new event driving RGEN's price, showing a major growth move.
Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.
This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.
Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.
It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.
Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.
This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Personalis Inc (PSNL)

Q3 202620 Jul – 6 Oct 2026

▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.
The takeover itself is the single biggest force setting PSNL's price.
Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.
Legal challenges are a real counterweight that could change deal terms or timing.
Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.
The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.
Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.
This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

August 202620 Jul – 6 Oct 2026

▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.
The takeover itself is the single biggest force setting PSNL's price.
Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.
Legal challenges are a real counterweight that could change deal terms or timing.
Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.
The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.
Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.
This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

Latest20 Jul – 6 Oct 2026

▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.
The takeover itself is the single biggest force setting PSNL's price.
Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.
Legal challenges are a real counterweight that could change deal terms or timing.
Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.
The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.
Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.
This explains why PSNL trades near the deal price instead of rallying on takeover hopes.